Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
P/B ratio for Tactile Systems Technology, Inc. (TCMD)
P/B ratio as of 2023: 1.69
According to Tactile Systems Technology, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.69. At the end of 2022 the company had a P/B ratio of 1.90.
P/B ratio history for Tactile Systems Technology, Inc. from 2001 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.69 |
| 2022 | 1.90 |
| 2021 | 2.93 |
| 2020 | 6.97 |
| 2019 | 11.34 |
| 2018 | 9.87 |
| 2017 | 6.91 |
| 2016 | 2.45 |
| 2015 | 5.42 |
| 2014 | 6.00 |
| 2013 | 6.66 |
| 2001 | 0.00 |